drugset
drugset / Trial / NCT07559136

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity

NCT07559136 ↗

Phase 1 Not yet recruiting 48 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS9531 injection compared with placebo in adolescents with obesity

Timeline

Start
2026-05
Primary completion
2027-01
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown — —

Indications

No indication recorded.